Discipline of Pharmacology, University of Sydney, Camperdown, New South Wales, Australia.
J Nucl Med. 2011 May;52(5):677-80. doi: 10.2967/jnumed.110.086629. Epub 2011 Apr 15.
The translocator protein (TSPO) is expressed at low levels in the healthy human brain and is markedly upregulated in response to brain injury and inflammation. This increase in TSPO expression is correlated to the extent of microglial activation, making the measurement of TSPO density a useful indicator of active brain disease. Several classes of TSPO radioligands have therefore been developed and evaluated for use in PET, to track the progression and severity of neuroinflammatory disease. TSPO is also overexpressed in cancer and peripheral inflammation, making TSPO PET ligands possible candidates for the imaging of a multitude of pathologies. However, we currently possess a limited understanding about the molecular structure of TSPO and about the interaction of ligands with the protein. Furthermore, the incomplete characterization of multiple TSPO binding sites and the role of TSPO polymerization suggest that current interpretation of PET data may require further refinement.
转位蛋白(TSPO)在健康人脑内的表达水平较低,在脑损伤和炎症时显著上调。TSPO 表达的增加与小胶质细胞激活的程度相关,使 TSPO 密度的测量成为活跃性脑疾病的一个有用指标。因此,已经开发并评估了几类 TSPO 放射性配体用于 PET,以跟踪神经炎症性疾病的进展和严重程度。TSPO 在癌症和外周炎症中也过度表达,使得 TSPO PET 配体可能成为多种病理的成像候选物。然而,我们目前对 TSPO 的分子结构以及配体与蛋白质的相互作用了解有限。此外,多个 TSPO 结合位点的不完全表征以及 TSPO 聚合的作用表明,目前对 PET 数据的解释可能需要进一步完善。